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Abstract
Background: Interaction of a drug or chemical with a biological system can result in a gene-
expression profile or signature characteristic of the event. Using a suitably robust algorithm these
signatures can potentially be used to connect molecules with similar pharmacological or
toxicological properties by gene expression profile. Lamb et al first proposed the Connectivity Map
[Lamb et al (2006), Science 313, 1929–1935] to make successful connections among small
molecules, genes, and diseases using genomic signatures.
Results: Here we have built on the principles of the Connectivity Map to present a simpler and
more robust method for the construction of reference gene-expression profiles and for the
connection scoring scheme, which importantly allows the valuation of statistical significance of all
the connections observed. We tested the new method with two randomly generated gene
signatures and three experimentally derived gene signatures (for HDAC inhibitors, estrogens, and
immunosuppressive drugs, respectively). Our testing with this method indicates that it achieves a
higher level of specificity and sensitivity and so advances the original method.
Conclusion: The method presented here not only offers more principled statistical procedures
for testing connections, but more importantly it provides effective safeguard against false
connections at the same time achieving increased sensitivity. With its robust performance, the
method has potential use in the drug development pipeline for the early recognition of
pharmacological and toxicological properties in chemicals and new drug candidates, and also more
broadly in other 'omics sciences.
Background
One of the most fundamental challenges in all forms of
'omic technologies is the connection of biological event
signatures with others previously derived to allow the rec-
ognition of new molecule properties or biological altera-
tion. Simple, robust, and efficient matching methods are
required to connect a new gene expression signature with
those in a database. This problem was first tackled by
Lamb et al [1] who introduced the Connectivity Map as a
resource and tool to connect small-molecule drugs, genes,
and diseases. The Connectivity Map achieved a good
degree of success, but also suffered from several deficien-
cies, particularly an inability to apply a measure of statis-
tical validity at the individual reference signature level to
allow rational filtering of the results to exclude false con-
nections. We took the method of Lamb et al as a basis for
development and have derived a simple, robust and statis-
tically testable method for making connections between
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biological event signatures. The method was tested with
genomic signatures resulting from small molecule interac-
tions in cells, but also could be applied to any form of sig-
nature such as those from proteomic or metabolomic
science.
The main assumption behind the concept of a connectiv-
ity map is that a biological state, whether physiological,
pathological, or induced with chemical or genomic per-
turbations, can be described in terms of a genomic signa-
ture, eg., the genome-wide mRNA levels as measured by
DNA microarray technologies. The working of a connec-
tivity map involves several key components. First, a large
collection of pre-built reference gene-expression profiles
serve as the core database, where each reference profile
characterizes a well-defined biological state. Secondly, a
query gene signature from some specific studies. A query
gene signature is basically a short (as compared to the list
of genes in a typical reference profile) list of genes most
relevant and important to characterize the biological state
of the researchers' interest. Finally, a pattern matching
algorithm or similarity metric defined between a query
gene signature and a reference gene-expression profile to
quantify the closeness or connection between the two bio-
logical states. Such a connectivity map can be used by bio-
medical researchers to find connections between the
reference biological states and those of their own interest,
leading to testable new biological hypotheses. In this
paper, we present a new framework for the construction of
reference profiles, new connection scoring scheme and
testing procedures for the observed connections. We com-
pare our method with that of Lamb et al, and show that
more robust results are achieved using our method. In
particular our method not only offers a more principled
statistical procedure for testing connections, but more
importantly it provides effective safeguards against false
connections while at the same time achieving increased
sensitivity. As a consequence it can benefit the end users
by saving them time and resources in pursuing new bio-
logical hypotheses based on the findings of connectivity
maps.
Results
Construction of reference profiles
For the first-generation connectivity map, Lamb et al car-
ried out a series of gene-expression profiling experiments
[1], using 164 distinct small-molecule compounds in a
few selected human cell lines. Each treatment instance
consisted of one treatment sample and one (or more)
vehicle control samples, whose genome wide mRNA lev-
els were measured using Affymetrix GeneChip microar-
rays. In total 564 samples were microarrayed, which
represented 453 different treatment instances. For exam-
ple, treatment instance ID988 consisted of 1 treatment
sample and 6 vehicle control samples. The treatment sam-
ple was obtained by treating human MCF7 cells with 100
nM  estradiol for 6 hours. The control samples were
obtained by treating MCF7 cells with vehicle control for 6
hours. A gene-expression profile was constructed for each
treatment instance, in which the relative expression (treat-
ment relative to the control) of all the measured genes
were specified, and sorted in descending order. A query
gene signature, obtained and ordered in the same manner,
can be compared to each reference profile in the Connec-
tivity Map to calculate a connectivity score. For "positive
connectivity", the up-regulated genes of the query signature
find matches near the top of the reference profile, and the
down-regulated genes find matches near the bottom of
the reference profile. For "negative connectivity", the
matches are opposite.
We obtained Lamb et al's data set (Accession Number
GSE5258) from the GEO (Gene Expression Omnibus)
database, and rebuilt the 453 reference gene-expression
profiles using a new ranking scheme based on the follow-
ing guiding principles: (1) A treatment instance was
defined relative to a control, thus the effect of the treat-
ment could be characterized by the relative differential
expression status of all the genes together, (2) different
genes were affected to different extents by the treatment,
so genes which showed a greater differential expression
should have more weight in characterizing this treatment,
and (3) up- and down-regulated genes should be treated
equally in a unified manner. This meant that a 2-fold
down-regulated gene was considered as equally important
as a 2-fold up-regulated gene in defining a reference pro-
file. There are several reasons for the choice of treating up-
and down-regulated genes equally. Theoretically, unless
we have a lot of further information about so many genes
on the microarray it is difficult to decide whether this 2-
fold up-regulated gene is more important than that 2-fold
down-regulated gene or the opposite. So it is logical to
assign them equal weights. Another reason is the consid-
eration of symmetry: if a gene is 2-fold up-regulated in
sample 1 versus sample 2, it can also be viewed as 2-fold
down-regulated in sample 2 versus sample 1. We should
emphasize that assigning two genes equal weights does
not imply in any sense they share the same molecular
mechanism. Even two up-regulated genes with the same
fold change could be involved in very different molecular
mechanisms. To adhere to the above guidelines, an obvi-
ous choice for organizing the genes is the logarithm of the
expression ratio (treatment over control). Thus instead of
treating the down- and up-regulated genes separately as in
the method of Lamb et al, we ordered genes in a reference
profile by the absolute value of their expression log-ratios.
Therefore the most differentially expressed genes (either
up or down) appear first in the list, and those non-differ-
entially expressed genes appear at the bottom of the list.
In this way, the genes are ordered by their importance inBMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
Page 3 of 10
(page number not for citation purposes)
defining the reference profile. It is then straightforward to
assign ranks to them. Suppose there are in total N genes,
the first gene in the list will be assigned a rank N if it is up-
regulated, or a rank -N if it is down-regulated. In general
the ith gene in the list will be ranked with (N - i + 1) for
up-regulation or - (N - i + 1) for down-regulation. With
this new ranking method, the importance of a gene is
reflected by the absolute value of its rank, while the sign
of its rank indicates its regulation status. The consequence
and advantage of this method for creating reference pro-
files is that attaching statistical significance to the connec-
tion observed is a relatively straightforward step.
The scoring scheme
A query gene signature can be an ordered gene list, or just
a collection of genes without specific ordering. We will
refer to these two types of query gene signatures as ordered
and unordered gene signatures respectively. For an ordered
gene signature, we rank the genes in the list in the same
way as for a reference profile. Namely, the most important
(differentially expressed) gene in the signature will be
assigned a rank m or -m depending on its regulation sta-
tus, where m  is the number of genes in the signature.
While the least important gene in the signature be ranked
1 or -1.
Let R denote a reference gene-expression profile, and s a
query gene signature. We define the connection strength
between R and s as
where gi represents the ith gene in the signature, s(gi) is its
signed rank in the signature, and R(gi) is this gene's signed
rank in the reference profile. It is worth noting some prop-
erties of the connection strength defined above: (1) if a
gene has the same regulation status (either up- or down-
regulation) in both the reference and the query, it will
make a positive contribution to the connection strength,
otherwise its contribution will be negative; (2) the magni-
tude of a gene's contribution to the connection strength is
determined by its position in both lists; and (3) a gene sig-
nature with some of its genes contributing positively and
others negatively will have an overall low connection
strength, because the positive and negative contributions
cancel each other to some extent. Therefore when calculat-
ing the connection strength between a gene signature and
a reference profile, the maximum connection strength
achievable is the situation where the m genes in the signa-
ture match the first m genes in the reference profile in the
correct order, and their regulation status also match. In
such a case, the maximum positive connection strength is,
for an ordered gene signature,
In another equally interesting situation, where the m
genes in the signature match the first m genes in the refer-
ence profile in the right order, but the sign of each gene in
the query is different from its sign in the reference, the
connection strength is  , the opposite of
Eq.(2).
For an unordered query signature, all the genes in the list
have equal weight because there is no particular ordering
among them. The calculation of connection strength is the
same as Eq.(1), the only difference being that s(gi) = 1 if
gene gi is up-regulated, or s(gi) = -1 if it is down-regulated.
Consequently, the maximum magnitude of connection
strength for an unordered signature is
Given a query signature gene and a reference gene-expres-
sion profile, we can calculate their connection score by
c = C(R, s)/Cmax(N, m). (4)
So a connection score c = 1 means that the gene signature
has the maximum positive connection strength with the
reference profile, which indicates that the experimental
condition that gave rise to this gene signature had the
strongest possible correlation with the treatment instance
that generated the reference profile. A connection score c
= -1 indicates that the two experimental perturbations
were most inversely correlated. In general, a connection
score c will be within the range of (-1, 1).
Connection Testing
As for most biomedical experiments with unavoidable
biological and technical variation, statistical significance
is a crucial aid to the interpretation and subsequent vali-
dation of the result. Here we propose calculating the p-
value associated with a connection score by testing the fol-
lowing null hypothesis.
Null hypothesis H0: For a reference gene-expression pro-
file R and a query gene signature s of length m, the null
hypothesis H0 states that there is no underlying biological
connection between the two, and that the query signature
s is merely a random m-gene signature, as generated by
Procedure 1 described below.
Procedure 1: Generation of a random m-gene signature.
Let R be a given reference gene-expression profile of N
CR g s g ii
i
m
(, ) () () , Rs =
= ∑
1
(1)
CN m N i m i max
o
i
m
( , ) ( )( ). =− + − +
= ∑ 11
1
(2)
−CN m max
o (,)
CN m N i max
u
i
m
(,) ( ) . =− +
= ∑ 1
1
(3)BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
Page 4 of 10
(page number not for citation purposes)
genes. Select m genes sequentially and randomly from the
N genes (without replacement), and assign +1 (up-regula-
tion) or -1 (down-regulation) randomly with equal prob-
ability to each of the m  selected genes. If this gene
signature is to be used as an ordered list, its order is just
the order in which the m genes are selected; or if this gene
signature is to be used as merely a collection of genes, then
the order is irrelevant.
Given a reference profile R and a gene signature s, we cal-
culate their connection score c by Eq.(4), and the two-
tailed p-value associated with this observed connection
score is
where   is the connection score between a random gene
signature and the reference profile. To estimate the p-
value, a large number (eg., 105) of random gene signa-
tures of the same length m can be generated using Proce-
dure 1 and their connection scores to reference profile R
calculated using Eq.(4), the proportion of random scores
that are no less than the observed scores c in absolute
value is an estimate of the two-tailed p-value.
The 453 individual treatment instances of the data set
GSE5258 were created using only 164 distinct small-mol-
ecule compounds. Some treatment instances were replica-
tion experiments using the same compound at the same
or different doses. It is thus interesting to consider all the
treatment instances of the same compound as a set, and to
assess the overall connection of the set with a query gene
signature.
We define the connection score for a treatment set as fol-
lows
where n is the number of individual treatment instances
belonging to the treatment set, ci is the connection score
of the ith instance. To test the significance of a treatment
set as a whole. We used the following null hypothesis,
Null hypothesis  : Where T denotes a set of treatment
instances,  Ri  the reference profile based on treatment
instance i, and s a query gene signature of length m, the
null hypothesis   states that there is no underlying
biological connection between the gene signature s and
any of the reference profiles in T. The query signature is
merely a random m-gene list generated by Procedure 1.
Thus the null hypothesis   is an extension of H0 to a
higher level. Alternatively, H0 can be viewed as a special
case of  , in which there is only one treatment instance
in the treatment set. Once the connection score for a set is
observed, its associated p value can be estimated in a sim-
ilar way: a large number of random gene signatures of the
same length m are generated using Procedure 1, and the
connection score of the set to each of the random gene sig-
natures is calculated using Eq.(6); the proportion of ran-
dom connection scores that are greater than the observed
score in absolute value is an estimation of the p value.
Testing with random gene signatures
To compare the specificities of the original Connectivity
Map and the method presented here, we generated ran-
dom gene signatures and tested these random gene signa-
tures in both. The first example was a random gene
signature, rds01, which contained 25 Affymetrix probe-set
IDs randomly selected from the 22283 IDs on the Affyme-
trix HG-U133A microarray platform. Querying the Con-
nectivity Map with this signature, we obtained the
connectivity scores of rds01 to all the 453 individual treat-
ment instances. The results are shown in Table 1, where
113 individual reference profiles have positive connectiv-
ity scores ranging from 1 to 0.342; 83 individual reference
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Table 1: Results for rds01 using the Connectivity Map.
rank ID compound score up down
1 1080 sirolimus 1 0.232 -0.578
2 913 colforsin 0.953 0.245 -0.527
3 1138 phentolamine 0.912 0.316 -0.423
4 1048 alpha-estradiol 0.886 0.324 -0.394
5 1115 phenanthridinone 0.869 0.379 -0.325
... ... ... ... ... ...
112 885 5186223 0.363 0.137 -0.157
113 3 metformin 0.342 0.158 -0.119
114 663 U0125 0 0.405 0.194
115 124 mesalazine 0 0.371 0.256
... ... ... ... ... ...
369 1008 geldanamycin 0 -0.43 -0.339
370 1064 17AAG 0 -0.436 -0.395
371 605 monastrol -0.38 -0.114 0.177
372 494 fluphenazine -0.392 -0.113 0.187
... ... ... ... ... ...
449 601 MK-886 -0.834 -0.303 0.336
450 604 arachidonic acid -0.855 -0.301 0.354
451 387 estradiol -0.901 -0.162 0.528
452 379 cobalt chloride -0.916 -0.238 0.464
453 378 tacrolimus -1 -0.23 0.536
The connectivity scores of the random gene signature rds01 to the 
reference profiles in the Lamb Connectivity Map. The full tabulated 
results can be found in the supplementary data [see Additional file 1]. 
113 reference profiles have positive connectivity scores, 83 reference 
profiles have negative connectivity scores.BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
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profiles have negative connectivity scores ranging from -1
to -0.38; and the remaining 257 reference profiles have a
null connectivity score 0. However, there is no p value or
other statistical significance measure associated with these
connectivity scores, so users cannot effectively control
possible false connections. In this case, because rds01 was
a random gene signature, all these positive and negative
connections must be false, including the top ones with
connectivity scores +1 and -1. So, regardless of what cut-
off score is used to call significant connections, all such
declared significant connections are false.
We then used this same random signature to test the new
method presented in this paper (Table 2). With a p value
calculated for each observed connection score, we can
control the expected number of false connections by set-
ting an appropriate threshold p value. In this paper, the
threshold p value is generally set at 1/N, where N is the
number of null hypotheses being tested simultaneously.
In this example, N = 453 (the total number of individual
treatment instances in the database and hence the number
of null hypothesis being tested at the treatment instance
level). So a connection with a p value p < 1/453 = 0.0022
is considered as statistically significant. The setting of the
threshold p value at 1/N  was intended to control the
expected number of false connections at 1, we thus
expected to have one false connection on average among
all the connections declared as significant. Table 2 shows
that our method gave the correct result, ie., no significant
connection between this random signature and any of the
treatment instances. Note that to control the expected
number of false connections more precisely, the threshold
hold p value should be set at 1/N0, where N0 is the
number of true null hypothesis. Of course in a general sit-
uation N0 is unknown, so it has to be estimated, for exam-
ple, using the methods developed in [2,3]. In this paper,
we set the threshold p value at 1/N for simplicity. Since N0
≤ N, our criteria tend to be slightly conservative, meaning
that the actual number of false connections on average
will be ≤ 1. The second random gene signature, rds02,
consisted of 189 Affymetrix probe-set IDs randomly
selected from 22283. The full results of querying the Con-
nectivity Map with this signature can be found in the sup-
plementary data [see Additional file 1], where 107
reference profiles have positive connectivity scores rang-
ing from +1 to +0.384, 119 reference profiles have nega-
tive connectivity scores ranging from -1 to -0.383, and the
remaining 227 reference profiles have a null connectivity
score 0. However, once again we know these positive and
negative connections must be all false, including the top
ones with connectivity scores +1 and -1. In contrast, the
method presented in this paper gave results that agree
with the known truth. With the criteria set above there was
1 connection found significant (p  < 1/453 = 0.0022).
Since we expect on average 1 false connection, this
declared significant connection can be taken as false.
The two examples of random gene signatures above
showed that on an individual treatment instance level, the
Connectivity Map does not provide effective safeguards
against possible false connections. On the treatment set
level, the Connectivity Map provides a permutation p
value when a set of treatment instances associated with
the same compound were viewed as a whole. The signifi-
cance of the set of treatment instances in the ordered list
of all instances was estimated by permutation (see the
Supporting Online Material for [1]). Note that the null
hypothesis   we use in our set-level analysis is differ-
ent from that of the Connectivity Map. Tian et al were
among the first groups of authors who made explicit dis-
tinctions between two different null hypotheses [4] con-
cerning a set of entities (a set of genes in context of Tian et
al's paper). Other authors also addressed this issue in
some recent studies on the significance analysis of gene
sets [5,6]. A more detailed comparison between the null
hypotheses used by the set-level analysis of the Connectiv-
ity Map and the method presented here can be found in
the supplementary information [see Additional file 2].
Throughout this paper, when we use the permutation p
values from the Connectivity Map to control false connec-
tions, the same criteria discussed above for setting thresh-
old p value are used. The full tabulated results of
significance analysis on the connections between the two
random gene signatures and the 164 treatments sets can
be found in the supplementary data. Both our method
and the Connectivity Map gave the right answers for these
two random gene signatures, ie, no significant connec-
tions were found more than expected by chance. There-
fore the set-level analysis of the Connectivity Map can
provide a control over possible false connections by
H
set
0
Table 2: Results for rds01 using the new method.
Rank Compound ID score pvalue
1 (-)-catechin 1101 0.334 0.003
2 sirolimus 1022 0.312 0.006
3 phentolamine 1138 0.309 0.007
4 5162773 892 0.292 0.011
5 resveratrol 595 0.286 0.013
... ... ... ...
451 felodipine 848 -0.002 0.988
452 estradiol 988 -0.001 0.991
453 bucladesine 959 0.001 0.993
The connection scores for the random gene signature rds01 using the 
new method. To control the expected number of false connections at 
1, the threshold p value was set at 1/453 = 0.0022. No connection 
was found to be significant, which agrees with the known truth.BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
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means of permutation p values. So in the subsequent
analysis on the experimentally derived gene signatures, we
only use the set-level results of the Connectivity Map, but
not its instance-level results. We need to point out that, in
the Connectivity Map set-level analysis, permutation p
values were not available for all the 164 treatment sets.
For those treatment sets which only contain 1 treatment
instance or those sets with mean connectivity score 0, no
permutation p values could be calculated, and hence no
statistical significance is attached to them. This problem
affects the coverage and consequently the sensitivity of the
Connectivity Map, because real biological connections
between a query gene signature and any of those treat-
ment sets may not be recognized.
Testing with experimentally derived gene signatures
HDAC inhibitors
To test the ability of the new method for identifying real
biological connections we utilized some of the same
examples used in [1] to compare with the Connectivity
Map. The first example was a gene signature of histone
deacetylase (HDAC) inhibitors (Lamb's gene signature
sigs01), which was compiled from an independent study
[7] on the responses of T24, MDA435 and MDA468 cells
respectively to three histone deacetylase (HDAC) inhibi-
tors: vorinostat, MS-27–275, and trichostatin A. This gene
signature consisted of 8 up- and 5 down-regulated genes,
represented by 25 Affymetrix probe-set IDs on the Affyme-
trix HG-U133A microarrays.
As the Connectivity Map does not provide effective safe-
guards on individual treatment instance level against pos-
sible false connections, we can only use the results of the
Connectivity Map on the treatment set level. In total 6
compounds (vorinostat, trichostatin A, resveratrol,
geldanamycin, valproic acid, and 17AAG) were identified
to have significant positive connectivity with the HDAC
inhibitor gene signature; and 2 compounds (5182598
and fludrocortisone) had significant negative connectiv-
ity. Vorinostat, trichostatin A, and valproic acid are known
HDAC inhibitors thus the identification of these can be
regarded as a success of the Connectivity Map. However
another known HDAC inhibitor HC-toxin, a reference
profile of which was contained in the database, was not
identified. This happened because there was only one
treatment instance of the compound HC-toxin in the
database and so no permutation p value could be
obtained using the Connectivity Map. Based on their
instance level results, Lamb et al highlighted HC-Toxin in
[1] as it had the 7th highest connectivity score (0.914) of
all instances in the dataset. However, the two examples of
random gene signatures already showed that at the
instance level the Connectivity Map gave false connec-
tions even for the highest connectivity scores +1 and -1. So
the rational choice is to disregard the instance level results
from the Connectivity Map.
We used this same HDAC inhibitor gene signature to test
the new method presented here, with p values calculated
at both the individual instance level and the treatment set
level. On the individual instance level, 56 treatment
instances, representing 22 distinct compounds, were
found to have significant connections to sigs01. On the
treatment set level, 24 compounds were found to have sig-
nificant connections with the signature. Near the top of
the significant connection list were those known HDAC
inhibitors highlighted in [1]. Importantly though also
included in the output was HC-Toxin, which was not
identified by the set-level analysis of the Connectivity
Map. The full tabulated results for the HDAC inhibitor
gene signature are included in the supplementary data. In
Fig. 1, we summarize the number of significant connec-
tions as identified by: (A) Instance level analysis using the
new method presented here; (B) Set level analysis using
the new method; (C) Set level analysis using the Connec-
tivity Map. In total, our method (A) and (B) combined
identified 27 compounds, while the Connectivity Map
identified 8 compounds, as having significant connec-
tions to the HDAC inhibitors. Our method missed only 1
of the 8 compounds found significant by the Connectivity
Map, while the latter missed 20 of the 27 compounds
identified by our method, with HC-toxin among the 20
compounds that were missed. The HDAC inhibitors
example thus shows that our method has a greater sensi-
tivity for detecting real connections. With the increased
sensitivity and false connections being properly control-
led, the potential benefit of our method is obvious. In this
example, the set-level analysis of the Connectivity Map
identified 8 compounds with a false discovery rate of
12.5% (1/8), while the set-level analysis using our
method identified 24 compounds with a false discovery
rate of 4.2% (1/24). Based on the findings of significant
connections, researchers can prioritize a small sub set of
those compounds for further investigations and/or devel-
oping new biological hypotheses. For this example, using
the Connectivity Map, the chance of pursuing a false con-
nection is 12.5%, while using our method it is much
lower at 4.2%. In practice this would save time and
resources and increase the rate of success.
Estrogens
The second example was a gene signature (Lamb's gene
signature sigs02) taken from an independent study [8] of
MCF7 cells treated with estradiol. This gene signature con-
sisted of 40 up- and 89 down-regulated genes represented
by 189 Affymetrix probe-set IDs on the Affymetrix HG-
U133A microarrays. We tested the Connectivity Map and
the method presented in this paper with this estrogen sig-
nature.BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
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For the same reason given above, we only used the treat-
ment set level results of the Connectivity Map, which
identified 4 compounds (genistein, estradiol, tretinoin,
and alpha-estradiol) as having significant positive con-
nectivity with the estrogen signature; and 5 compounds
(trichostatin A, fulvestrant, LY-294002, vorinostat, and
geldanamycin) that had significant negative connectivity.
Using our set-level analysis 16 compounds were found to
have significant positive connection, and 25 compounds
had significant negative connection to the estrogen gene
signature. The 16 compounds with positive connection
included genistein, estradiol, and alpha-estradiol, all
known to be estrogen receptor agonists. The 25 com-
pounds with negative connection included fulvestrant,
raloxifene and tamoxifen, all known to be estrogen recep-
tor antagonists. In comparison, the Connectivity Map
identified all the estrogen receptor agonists above, but
missed all the estrogen receptor antagonists except fulves-
trant. These results therefore indicate the sensitivity of our
method is substantially increased. The Connectivity Map
was able to detect the pure estrogen receptor antagonist
fulvestrant, but missed the two compounds tamoxifen
and raloxifene which have mixed antagonist and agonist
estrogen receptor activities.
The results from our set level analysis also suggest that
nordihydroguaiaretic acid (NDGA) has significant posi-
tive connection with estradiol. This connection is sup-
ported by recent studies [9,10], where NDGA has been
shown to have estrogenic activity and able to elicit an
estrogen-like response. Another compound monorden
(radicicol), suggested by our method as having negative
connection to the estrogen gene signature, has been
shown to repress the transcriptional function of the estro-
gen receptor [11] which suggests that it may have some
estrogen receptor antagonist-like properties. The full tab-
ulated results for the estrogen gene signature are included
in the supplementary data. Fig. 2 summarizes the num-
bers of significant connections identified by our method
and by the Connectivity Map. All 9 compounds found sig-
nificant by the Connectivity Map were also identified by
Results for the HDAC inhibitor gene signature Figure 1
Results for the HDAC inhibitor gene signature. The Venn diagram summarizing the findings of significant connections. A 
represents the instance-level analysis using our new method; B, the set-level analysis using the new method; C, the set-level 
analysis using the Connectivity Map. The label "AB 13" means that 13 compounds are identified as significant solely by A and B 
(not C), "B 4" means that 4 compounds are identified as significant solely by B (not A, not C), and so on. The areas are approx-
imately proportional to the numbers they represent.BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
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the our method (either on the instance level or on the set
level or both). However many compounds identified as
significant with either positive or negative connection to
estradiol using our method were not identified by the
Connectivity Map, included amongst these were
raloxifene, tamoxifen, monorden, and NDGA.
Immunosuppressive therapy
For further testing we compiled a new gene signature from
an independent study on cardiac allograft rejection and
response to immunosuppressive therapy [12], where
patients were treated with standard immunosuppression
with corticosteroids, antimetabolites, calcineurin inhibi-
tors, and/or sirolimus. This gene signature consisted of 40
Affymetrix probe set IDs (see Table 2 of [12]). Our set-
level analysis identified 29 compounds as having signifi-
cant connections with this gene signature. The three top
compounds were azathioprine, thalidomide, and rosigli-
tazone. Azathioprine is a commonly used immunosup-
pressive drug [13,14], so its significant positive
connection with the gene signature is a good indication
that the new method works very well here. The second
compound thalidomide, which had a positive connection
score, also has known immunosuppressive activities [15],
inhibits release of TNFα from monocytes, and modulates
other cytokine actions. The recognized properties of these
molecules therefore accord with the outcome of the con-
nectivity matching. The third compound rosiglitazone
had a negative connection with the signature suggesting it
may have properties to reduce or mitigate the effects of
immunosuppressive activity. Recently, rosiglitazone was
reported to suppress cyclosporin-induced chronic trans-
plant dysfunction and prolong survival of rat cardiac allo-
grafts [16], where cyclosporin is also a commonly used
immunosuppressive drug [17].
At the instance level, our method identified 89 reference
profiles as having significant connections to the immuno-
suppressive drug gene signature, representing 63 distinct
compounds. The top 3 compounds were azathioprine,
staurosporine, and trichostatin A, which all achieved pos-
itive connection scores with this gene signature. The sec-
ond compound, staurosporine, a protein kinase C
inhibitor, is classified as an antineoplastic and immuno-
suppressive antibiotic drug [18]. The third compound, tri-
chostatin A, was recently shown to have some
immunosuppressive effects in leukemia T cells [19].
Therefore the method of instance testing could be partic-
Results for the Estrogen gene signature Figure 2
Results for the Estrogen gene signature. The Venn diagram summarizing the findings of significant connections as identi-
fied by the Connectivity Map and the new method here. The labelling follows the same conventions as in the previous figure.BMC Bioinformatics 2008, 9:258 http://www.biomedcentral.com/1471-2105/9/258
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ularly valuable for the identification of pharmacological
and toxicological properties in novel molecules.
Discussion
Our results indicate that the method presented here can
identify many significant connections to a query gene sig-
nature. Then what criteria should we use and which com-
pounds should we choose if new biological hypotheses
are to be developed? Our suggestion is to concentrate
more on those compounds which have many replicate
instances in the database. Because the results obtained for
those big treatment sets do not depend heavily on the
quality of a small number of treatment instances, as in the
case of small treatment sets or singleton sets (treatment
sets with only 1 instance each). Lamb et al also recognized
the importance of having replicate instances, and noted
that the power to detect connections might be greater for
compounds with many replicates. In defining a treatment
set, ideally only the treatment instances of the same com-
pound with the same dose and the same cell type should
be considered as a set. For example, the biological state of
HL60 cells perturbed by raloxifene should be considered
as a different biological state from that of MCF7 cells per-
turbed with the same compound, thus these two instances
of raloxifene should not be put into the same set. In this
paper for comparative purposes we adopted Lamb et al's
choice in defining a treatment set, i.e., all the instances of
a compound were grouped together as a set regardless of
their possible differences in dose or cell type. Mixing the
instances of a compound with different doses and/or dif-
ferent cell types increases the heterogeneity of an other-
wise more homogenous treatment set. This tends to
average out the distinct characteristics attributable to the
cell type or dosage difference, making some set-level con-
nections insignificant or their interpretation difficult. In
such cases the instance level connections supported by
statistical significance can be of great help in interpreting
the results. For future connectivity maps, efforts should be
made to provide as many replicate treatment instances
(replicates with the same compound, the same dose, and
the same cell type, etc) as possible, so that the undesirable
reliance on individual instances can be minimized.
The successful identification of real biological connec-
tions between the reference profiles and a gene signature
also depends on the quality of the gene signature. In this
paper, all the three experimentally derived signatures were
compiled from independent studies, in which the original
authors had selected those genes as most relevant to char-
acterize the biological states being studied. It is reasonable
to ask though how many genes should be selected from
the full list of genes on the microarray to best characterize
a biological state? We believe this will depend on the spe-
cific biological condition being investigated, and is the
decision of the individual investigator. It is expected that
only those genes that show significant differential expres-
sion should be included in the gene signature. In our
experience, as also shown by the examples here, gene sig-
natures with length in the order of 10 to 100 work well,
but this can only serve as a rough guide. A Java application
implementing the method presented in this paper can be
downloaded via FTP from our institution's website [see
Additional file 3].
Conclusion
We have presented in this paper a framework for a new
connectivity map, with the advantages that statistical sig-
nificance measures are calculated at both treatment
instance level and treatment set level, thus providing
effective control over false connections. This important
safeguard was not available in the original Connectivity
Map at the instance level, as revealed by the two examples
of random gene signatures. As the connectivity maps are
most useful for high throughput screening and for gener-
ating new biological hypothesis, it is crucial that false con-
nections are tightly controlled. We compared the
performance of the method here with the original Con-
nectivity Map using two gene signatures (for HDAC inhib-
itors and estrogens respectively) previously compiled in
[1] and also a new gene signature for immunosuppressive
drugs. All these examples demonstrated that our method
is more sensitive and robust than the original. With its
increased sensitivity and with false connections being
properly controlled, the method presented here can
potentially benefit biomedical researchers by saving them
time and resources and increasing their rate of success in
pursuing new biological hypothesis based on the findings
of connectivity maps.
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